- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04132856
Mapping Psychosocial Screening to Services for Children With Cancer
Mapping Psychosocial Screening to Services for Children With Cancer: Feasibility and Pilot Study
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Background: Approximately 3 000 children and adolescents are diagnosed with cancer in Canada each year [Canadian Cancer Society]. Children with cancer experience higher rates of anxiety and depression symptoms relative to healthy controls [Pinquart & Shen, 2011], and a subgroup are vulnerable to marked levels of psychological distress [Kurtz & Abrams, 2011]. One standard for psychosocial care in pediatric cancer that is starting to be implemented across the United Stated and Canada is the systematic screening for psychosocial distress, using the Psychosocial Assessment Tool (PAT) [Kazak, Schneider, Didonato, Pai, 2015; Pai et al., 2008; Barrera et al., 2014; McCarthy et al., 2009; Sint Nicolaas et al., 2016]. However, a dearth of literature exists on how to bridge screening for psychosocial distress and the delivery of appropriate evidence-based mental health resources. The current study is a randomized controlled pilot intervention project which aims to test the feasibility and effects of introducing a psychosocial navigator who will coordinate the delivery of psychosocial resources to children with cancer and their families based on early screening and follow-up for psychosocial distress. Specific Objectives: 1) To determine the feasibility and utility of conducting psychosocial screening and providing an Enhanced Psychosocial Intervention (EPSI). 2) To examine the effects of EPSI, as compared to treatment as usual (TAU+), on the mental health, quality of life, coping, and social relationships of children with cancer. Methods: A randomized controlled feasibility intervention trial, with a TAU+ control group, will be conducted with newly diagnosed children with any type of cancer. Participants will be 10-18 years of age, medically suitable for participation, in active treatment, and the primary caregiver. Forty-eight child-caregiver dyads (24 in the intervention and 24 in the control group) will be enrolled. The EPSI will have two components: 1) Information about the psychosocial risk of the family and mental health of the child (e.g., depression) and 2) the Psychosocial Navigator (PSN) as resource for tailoring psychosocial resources to child-family distress, linking with the treating team. Measures of feasibility (recruitment, acceptability) will be documented throughout; initial screening using the PAT will be conducted 2-4 weeks post diagnosis (baseline); and using the distress thermometer, follow-up will be done at specific periods depending on the disease (leukemia/lymphoma, solid tumors, brain tumors). The primary psychosocial outcome (depression), and secondary outcomes (post-traumatic stress, pain, fatigue, coping, sleep quality, time and financial cost, social support and quality of life) will be completed at baseline and 12 months later. Descriptive statistics (frequency and percentage rates) will be provided for feasibility measures and PAT psychosocial risk categories. Means, standard deviations, and ranges will be provided for the primary and secondary outcomes. Preliminary analyses of group comparisons will also be performed via independent t tests and chi square tests. Further, analyses of covariance (ANCOVAs) will be conducted on the primary and secondary outcomes to test group differences at post-test while controlling for pretest scores.
Significance: The proposed intervention project will assess and address the psychosocial needs of newly diagnosed pediatric cancer patients and families. This intervention aims to improve the triaging of resources and enhance the effectiveness of psychosocial intervention for children with cancer. The enhanced intervention is expected to improve children's and adolescents' coping with disease-related stressors such as pain and uncertainty, improve their mood, and enhance social engagement with peers.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M4G 3R9
- Hospital for Sick Children
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Between 10 and 18 years of age
- Clinical diagnosis of cancer
- Less than 4 weeks since diagnosis disclosure
- Primary caregiver must also consent to participation
Exclusion Criteria:
- Cancer diagnosis disclosed more than 4 weeks ago.
- Primary caregiver declines to participate
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Selezione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervention Group
The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study.
At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures).
This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion.
The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers.
Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
|
Services of psychosocial navigator
Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
|
|
Nessun intervento: Treatment as Usual Group
Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility pertaining to recruitment
Lasso di tempo: 12 months
|
Rate of recruitment as measured by percentage of participants who consent to participation as compared to those who are eligible and do not consent
|
12 months
|
|
Feasibility pertaining to retention
Lasso di tempo: 12 months
|
Rates of completed questionnaires at all time points
|
12 months
|
|
Satisfaction with Enhanced Intervention as assessed by questionnaire at completion of study
Lasso di tempo: 12 months
|
5 - point likert scale satisfaction questionnaire with 6 questions pertaining to usefulness and overall satisfaction with the enhanced intervention.
The minimum score is 6 (low satisfaction) and the maximum score is 30 (high satisfaction).
|
12 months
|
|
Satisfaction with Enhanced Intervention as assessed by semi-structured interview at completion of study
Lasso di tempo: 12 months
|
Semi-structured interview with 6 questions including "What were your expectations about being in this study?";
"Were your expectations of the study met?"; "Do you have any additional comments/suggestions for the study?"
|
12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Distress
Lasso di tempo: Change from baseline to 12 months
|
Pediatric and Adult Distress Thermometer (self-report) measures participant distress on a visual analog scale of 1 to 10, with a score of 10 indicating high distress
|
Change from baseline to 12 months
|
|
Patient generic quality of life based on self report
Lasso di tempo: Change from baseline to 12 months
|
Pediatric Quality of Life - generic.
(Child/teen self-report).
Measures perceived quality of life of child with cancer based on self perception - on everyday items (for children who do not have cancer).
Miinimum score is 0. Maximum score is 100.
Higher score indicates better perceived quality of life.
|
Change from baseline to 12 months
|
|
Patient generic quality of life based on caregiver report
Lasso di tempo: Change from baseline to 12 months
|
Pediatric Quality of Life - generic.
(Caregiver-report).
Measures perceived quality of life of child with cancer based on caregiver perception - on everyday items (for children who do not have cancer).
Miinimum score is 0. Maximum score is 100.
Higher score indicates better perceived quality of life.
|
Change from baseline to 12 months
|
|
Patient quality of life as it relates to cancer, based on self-report
Lasso di tempo: Change from baseline to 12 months
|
Pediatric Quality of Life-Cancer (Child/teen self-report).
Measures perceived quality of life of child with cancer based on self-perception.
Miinimum score is 0. Maximum score is 100.
Higher score indicates better perceived quality of life.
|
Change from baseline to 12 months
|
|
Patient quality of life as it relates to cancer, based on caregiver report
Lasso di tempo: Change from baseline to 12 months
|
Pediatric Quality of Life-Cancer (Caregiver report).
Measures perceived quality of life of child with cancer based on caregiver perception.
Miinimum score is 0. Maximum score is 100.
Higher score indicates better perceived quality of life.
|
Change from baseline to 12 months
|
|
Patient anxiety and depression - child/teem self report
Lasso di tempo: Change from baseline to 12 months
|
Pediatric Index of Emotional Distress.
Minimum score is 0. Maximum score is 42.
Lower score indicates lower levels of anxiety and depression.
|
Change from baseline to 12 months
|
|
Patient anxiety (child/teen self-report)
Lasso di tempo: Change from baseline to 12 months
|
Patient-reported Outcomes Measurement Information System (PROMIS) - pediatric anxiety questionnaire - short form (child/teen self-report).
Minimum score is 8. Maximum score is 40.
Lower score indicates lower level of anxiety.
|
Change from baseline to 12 months
|
|
Patient depression (child/teen self-report)
Lasso di tempo: Change from baseline to 12 months
|
Patient-reported Outcomes Measurement Information System (PROMIS) - pediatric depression questionnaire - short form (child/teen self-report).
Minimum score is 8. Maximum score is 40.
Lower score indicates lower level of depression.
|
Change from baseline to 12 months
|
|
Caregiver post-traumatic stress related to child's cancer diagnosis
Lasso di tempo: Change from baseline to 12 months
|
Impact of Events scale - Revised (IES-R) (caregiver self-report).
Mimimum score is 0. Maximum score is 88.
Lower scores indicate lower levels of post-traumatic stress.
|
Change from baseline to 12 months
|
|
Patient post-traumatic stress related to own cancer diagnosis
Lasso di tempo: Change from baseline to 12 months
|
Impact of Events scale - Revised (IES-R) (child/teen self-report).
Mimimum score is 0. Maximum score is 88.
Lower scores indicate lower levels of post-traumatic stress.
|
Change from baseline to 12 months
|
|
Caregiver coping with stress of child's cancer diagnosis
Lasso di tempo: Change from baseline to 12 months
|
Responses to Stress Questionnaire - Cancer Version (caregiver self-report).
Minimum score is 0. Maximum score is 1.
A higher score indicates more engagement with active coping strategies.
|
Change from baseline to 12 months
|
|
Patient's own coping with stress of cancer diagnosis
Lasso di tempo: Change from baseline to 12 months
|
Response to Stress Questionnaire - Cancer Version (patient self-report).
Minimum score is 0. Maximum score is 1.
A higher score indicates more engagement with active coping strategies.
|
Change from baseline to 12 months
|
|
Psychosocial risk
Lasso di tempo: Change from baseline to 12 months
|
Psychosocial Assessment Tool (PAT) (caregiver report).
Minimum score is 0. Maximum score is 3. Lower score indicates lower level of psychosocial risk.
|
Change from baseline to 12 months
|
|
Financial impact of pediatric cancer diagnosis and treatment on families.
Lasso di tempo: Change from baseline to 12 months
|
Financial burden questionnaire (caregiver report).
Minimum score is 22. Maximum score is 88.
Higher score indicates lower level of financial impact on families.
|
Change from baseline to 12 months
|
|
Caregiver depression
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Questionnaire (caregiver self-report).
Minimum score is 6.
Maximum score is 30.
Lower scores indicate lower levels of depression.
|
Change from baseline to 12 months
|
|
Caregiver anxiety
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Questionnaire (caregiver self-report).
Minimum score is 6.
Maximum score is 30.
Lower scores indicate lower levels of anxiety.
|
Change from baseline to 12 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sleep duration and quality of sleep of patient and caregiver
Lasso di tempo: Change from baseline to 12 months
|
Pittsburgh Sleep Quality Index.
(Caregiver and patient self-report).
Minimum value is 0. Maximum value is 21.
Lower scores indicate better sleep quality.
|
Change from baseline to 12 months
|
|
Caregiver emotional support
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Support Questionnaire (caregiver self-report).
Minimum score is 6.
Maximum score is 30.
Higher scores indicate higher levels of emotional support.
|
Change from baseline to 12 months
|
|
Caregiver Fatigue
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Questionnaire (caregiver self-report).
Minimum score is 6.
Maximum score is 30.
Lower scores indicate lower levels of fatigue
|
Change from baseline to 12 months
|
|
Patient Peer Relationships
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Perceived Quality of Peer Relationships (child/teen self-report).
Minimum score is 8. Maximum score is 40.
Higher scores indicate higher levels of perceived peer relationship quality.
|
Change from baseline to 12 months
|
|
Patient Fatigue
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Questionnaire (child/teen self-report).
Minimum score is 10.
Maximum score is 50.
Lower scores indicate lower levels of fatigue.
|
Change from baseline to 12 months
|
|
Patient emotional support
Lasso di tempo: Change from baseline to 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Support Questionnaire (child/teen self-report).
Minimum score is 7. Maximum score is 35.
Higher scores indicate higher levels of emotional support.
|
Change from baseline to 12 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Maru Barrera, PhD, The Hospital for Sick Children
Pubblicazioni e link utili
Pubblicazioni generali
- Barrera M, Hancock K, Rokeach A, Cataudella D, Atenafu E, Johnston D, Punnett A, Nathan PC, Bartels U, Silva M, Cassidy M, Jansen P, Shama W, Greenberg C. External validity and reliability of the Psychosocial Assessment Tool (PAT) among Canadian parents of children newly diagnosed with cancer. Pediatr Blood Cancer. 2014 Jan;61(1):165-70. doi: 10.1002/pbc.24774. Epub 2013 Sep 17.
- Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society; 2015.
- Pinquart M, Shen Y. Behavior problems in children and adolescents with chronic physical illness: a meta-analysis. J Pediatr Psychol. 2011 Oct;36(9):1003-16. doi: 10.1093/jpepsy/jsr042. Epub 2011 Aug 1.
- Kurtz BP, Abrams AN. Psychiatric aspects of pediatric cancer. Pediatr Clin North Am. 2011 Aug;58(4):1003-23, xii. doi: 10.1016/j.pcl.2011.06.009.
- Kazak AE, Schneider S, Didonato S, Pai AL. Family psychosocial risk screening guided by the Pediatric Psychosocial Preventative Health Model (PPPHM) using the Psychosocial Assessment Tool (PAT). Acta Oncol. 2015 May;54(5):574-80. doi: 10.3109/0284186X.2014.995774. Epub 2015 Mar 9.
- Pai AL, Patino-Fernandez AM, McSherry M, Beele D, Alderfer MA, Reilly AT, Hwang WT, Kazak AE. The Psychosocial Assessment Tool (PAT2.0): psychometric properties of a screener for psychosocial distress in families of children newly diagnosed with cancer. J Pediatr Psychol. 2008 Jan-Feb;33(1):50-62. doi: 10.1093/jpepsy/jsm053. Epub 2007 Jul 3.
- McCarthy MC, Clarke NE, Vance A, Ashley DM, Heath JA, Anderson VA. Measuring psychosocial risk in families caring for a child with cancer: the Psychosocial Assessment Tool (PAT2.0). Pediatr Blood Cancer. 2009 Jul;53(1):78-83. doi: 10.1002/pbc.22007.
- Sint Nicolaas SM, Schepers SA, Hoogerbrugge PM, Caron HN, Kaspers GJ, van den Heuvel-Eibrink MM, Grootenhuis MA, Verhaak CM. Screening for Psychosocial Risk in Dutch Families of a Child With Cancer: Reliability, Validity, and Usability of the Psychosocial Assessment Tool. J Pediatr Psychol. 2016 Aug;41(7):810-9. doi: 10.1093/jpepsy/jsv119. Epub 2015 Dec 29.
- Desjardins L, Hancock K, Szatmari P, Alexander S, Shama W, De Souza C, Mills D, Abla O, Barrera M. Protocol for mapping psychosocial screening to resources in pediatric oncology: a pilot randomized controlled trial. Pilot Feasibility Stud. 2021 Jul 17;7(1):143. doi: 10.1186/s40814-021-00878-0.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 1000056445
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
Prove cliniche su Psychosocial Navigator
-
University Medical Centre LjubljanaKarolinska Institutet; Schneider Children's Medical Center, IsraelCompletatoIpoglicemia | Diabete mellito, tipo 1Svezia, Israele, Slovenia
-
Lawson Health Research InstituteBoston Scientific CorporationTerminato
-
Florida State UniversityNational Institute of Mental Health (NIMH); Emory University; Weill Medical College... e altri collaboratoriCompletatoDisturbo dello spettro autisticoStati Uniti
-
HeartFlow, Inc.Reclutamento
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...Attivo, non reclutante
-
University of CalgaryCompletatoIpertensione | Diabete mellito, tipo 2 | Malattie renali croniche | Broncopneumopatia cronica ostruttiva | Asma | Cardiopatia ischemica | Insufficienza cardiaca congestiziaCanada
-
University of Wisconsin, MadisonAurora Health CareTerminatoCancro al seno | Cancro colorettale | Cancro ai polmoni | Cancro alla prostataStati Uniti
-
Abbott Diabetes CareLiverpool University Hospitals NHS Foundation Trust; NHS Lothian; Cardiff and Vale... e altri collaboratoriCompletato
-
University of California, RiversideNational Institute of Mental Health (NIMH); University of California, Los Angeles e altri collaboratoriNon ancora reclutamentoDepressione | Ansia | Problema di salute mentale